AOXG SEC-arkiveringar - Aoxing Pharmaceutical Company, Inc.- Årsredovisning, Fullmaktsutlåtande, prospekt

Grundläggande statistik

CIK

1060426

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Aoxing Pharmaceutical Company, Inc.

SEC Filings (Chronological Order)

Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.

October 17, 2017	15-12G	Aoxing Pharmaceutical 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specifi
October 6, 2017	25	Aoxing Pharmaceutical 25 OMB APPROVAL OMB Number:3235-0080 Expires: March 31, 2018 Estimated average burden hours per response 1.
September 28, 2017	AW	Aoxing Pharmaceutical AW AOXING PHARMACEUTICAL COMPANY, INC. 1098 Foster City Blvd., Suite 106-810 Foster City, CA 94404 September 28, 2017 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street N.E. Washington, DC 20549 Re: Aoxing Pharmaceutical Company, Inc. Request for Withdrawal on Form RW for Post-Effective Amendment to Registration Statement on Form S-3 filed on September 26, 2017
September 27, 2017	NT 10-K	Aoxing Pharmaceutical 12B25 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Expires: October 31, 2018 Washington, D.
September 27, 2017	POS AM	Aoxing Pharmaceutical POS AM As filed with the Securities and Exchange Commission on September 26, 2017 Registration Number 333-205148 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 POST-EFFECTIVE AMENDMENT NO.
September 26, 2017	S-3/A	Aoxing Pharmaceutical POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 As filed with the Securities and Exchange Commission on September 26, 2017 Registration Number 333-205148 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 POST-EFFECTIVE AMENDMENT NO.
September 23, 2017	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2017 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction of Incorporation)
September 23, 2017	EX-99.1	AOXING PHARMACEUTICAL ANNOUNCES DELISTING AND DEREGISTRATION OF COMMON STOCK Exhibit 99.1 AOXING PHARMACEUTICAL ANNOUNCES DELISTING AND DEREGISTRATION OF COMMON STOCK Foster City, CA/ PRNewswire/September 25, 2017 - Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) today announced that its board of directors has made a determination to remove the Aoxing Pharma Common Stock from the NYSE MKT. On September 25, 2017, Aoxing Pharma notified the NYSE MKT of its intention to f
August 4, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2017 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S. E
June 22, 2017	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2017 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction of Incorporation) (Com
May 15, 2017	10-Q	AXN / Aoxing Pharmaceutical Company, Inc. 10Q (Quarterly Report) United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10‑Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, INC.
May 11, 2017	DEFA14A	Aoxing Pharmaceutical PRIMARY DOCUMENT Unassociated Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
May 11, 2017	DEF 14A	Aoxing Pharmaceutical DEF 14A Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (As Permitted by Rul
February 17, 2017	10-Q/A	Aoxing Pharmaceutical 10-Q AMENDMENT NO. 1 (Quarterly Report) United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10?Q/A (Amendment No. 1) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2016 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMA
February 14, 2017	10-Q	Aoxing Pharmaceutical 10Q (Quarterly Report) United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10?Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2016 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, IN
November 14, 2016	10-Q	Aoxing Pharmaceutical 10Q (Quarterly Report) United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10?Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, I
October 5, 2016	10-K	Aoxing Pharmaceutical 10K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended June 30, 2016. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, INC. (Exact Name of Registrant as S
October 5, 2016	EX-21.1	List of Subsidiaries Exhibit 21.1 List of Subsidiaries The Company has the following subsidiaries: · Ostar Pharmaceutical, Inc., a Delaware corporation · Hebei Aoxing Pharmaceutical Co., Inc., a PRC company
October 5, 2016	EX-10.2	AOXING PHARMACEUTICAL COMPANY, INC. Exhibit 10.2 AOXING PHARMACEUTICAL COMPANY, INC. 2016 STOCK INCENTIVE PLAN 1. Purpose of Plan. The purpose of this Plan is to advance the interests of the Company and its shareholders by enabling the Company and its Subsidiaries to attract and retain qualified individuals to perform services for the Company and its Subsidiaries, providing incentive compensation for such individuals in a form that
September 28, 2016	NT 10-K	Aoxing Pharmaceutical 12B25 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Expires: May 31, 2012 Washington, D.
June 23, 2016	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2016 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction of Incorporation) (Com
May 16, 2016	10-Q	Aoxing Pharmaceutical AOXING PHARMACEUTICAL COMPANY, INC. 10Q 2016-03-31 (Quarterly Report) United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10‑Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, INC.
May 3, 2016	DEFA14A	Aoxing Pharmaceutical AOXING PHARMACEUTICAL COMPANY, INC. DEFA14A 2016-05-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ]
May 3, 2016	DEF 14A	Aoxing Pharmaceutical AOXING PHARMACEUTICAL COMPANY, INC. DEF 14A 2016-05-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ]
February 8, 2016	10-Q	AXN / Aoxing Pharmaceutical Company, Inc. 10-Q - Quarterly Report - AOXING PHARMACEUTICAL COMPANY, INC. 10Q 2015-12-31 10-Q 1 aoxing10q.htm AOXING PHARMACEUTICAL COMPANY, INC. 10Q 2015-12-31 United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10‑Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2015 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition peri
February 1, 2016	EX-10.1	Aoxing Pharmaceutical Company, Inc. Exhibit 10.1 ?????? CFO???? Aoxing Pharmaceutical Company, Inc. CFO Employment Contract ????????? Party A: Aoxing Pharmaceutical Company, Inc. ????? Party B: Zheng Chen ????????????????? Party A and Party B agreed to reach the following terms and conditions after friendly negotiation. ?. ?? Article 1. Employment 1.1???????? 2016? 2? 1??? 2018? 1? 31????? 3?? 1.1 Term: this contract would come into
February 1, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2016 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction of Incorporation) (
January 11, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2016 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S.
December 1, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2015 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S
November 13, 2015	10-Q	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10‑Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10?Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, I
October 21, 2015	EX-99.1	EX-99.1 exhibit99-1.htm Exhibit 99.1
October 21, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits aoxing8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2015 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Comm
October 13, 2015	EX-21.1	List of Subsidiaries Exhibit 21.1 List of Subsidiaries The Company has the following subsidiaries: ? Ostar Pharmaceutical, Inc., a Delaware corporation ? Hebei Aoxing Pharmaceutical Co., Inc., a PRC company
October 13, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended June 30, 2015. OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, INC. (Exact Name of Registrant as S
October 1, 2015	EX-10.B	COMMON STOCK PURCHASE WARRANT AOXING PHARMACEUTICAL COMPANY, INC. exhibit10b.htm Exhibit 10-b COMMON STOCK PURCHASE WARRANT AOXING PHARMACEUTICAL COMPANY, INC. Warrant Shares: Initial Exercise Date: March 30, 2016 Issue Date: September 30, 2015 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter se
October 1, 2015	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits aoxing8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2015 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Co
September 28, 2015	NT 10-K	Aoxing Pharmaceutical FORM 12B-25 aoxingnt.htm UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Expires: May 31, 2012 Washington, D.C. 20549 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 0-24185 NOTIFICATION OF LATE FILING CUSIP NUMBER 16937H106 (Check One): x Form 10-K o Form 20-F o Form 11-K ? Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June
September 28, 2015	424B5	Prospectus Supplement Filed pursuant to Rule 424(b)(5) (To Prospectus Dated July 1, 2015) Registration No. 333-205148 2,352,941 shares of common stock 1,905,882 common stock purchase warrants0 1,905,882 shares of common stock issuable upon exercise o aoxomg.htm Prospectus Supplement Filed pursuant to Rule 424(b)(5) (To Prospectus Dated July 1, 2015) Registration No. 333-205148 2,352,941 shares of common stock 1,905,882 common stock purchase warrants0 1,905,882 shares of common stock issuable upon exercise of the warrants Pursuant to this prospectus supplement and the accompanying prospectus, we are offering up to 4,258,823 shares of our common
September 25, 2015	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits aoxing8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2015 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Co
September 25, 2015	EX-10.A	SECURITIES PURCHASE AGREEMENT exhibit10-a.htm Exhibit 10-a SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of September 24, 2015, between Aoxing Pharmaceutical Company, Inc., a Florida corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subj
June 30, 2015	CORRESP	Aoxing Pharmaceutical ESP aoxing.htm AOXING PHARMACEUTICAL COMPANY, INC. 444 Washington Blvd., Suite 3338 Jersey City, NJ 07310 646-367-1747 June 30, 2015 Jeffrey P. Riedler Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Aoxing Pharmaceutical Company, Inc. Registration Statement on Form S-3 Filed June 22, 2015 Registration File No.: 333-205148 Dear Mr. Riedler
June 23, 2015	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders aoxing.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2015 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction of Incorpor
June 22, 2015	S-3	Aoxing Pharmaceutical AOXING PHARMACEUTICAL COMPANY, INC. S-3 2015-06-19 aoxomg.htm As filed with the Securities and Exchange Commission on June 22, 2015 Registration Number 333- - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State or Other Jurisdiction of incorporation o
June 22, 2015	EX-4.2	FORM OF INDENTURE TO BE ENTERED INTO BETWEEN THE COMPANY AND A TRUSTEE TO BE NAMED AOXING PHARMACEUTICAL COMPANY, INC. DATED AS OF , 2015 [Name of Trustee] TABLE OF CONTENTS aoxomgexh42.htm FORM OF INDENTURE TO BE ENTERED INTO BETWEEN THE COMPANY AND A TRUSTEE TO BE NAMED AOXING PHARMACEUTICAL COMPANY, INC. INDENTURE DATED AS OF , 2015 [Name of Trustee] TRUSTEE TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act. 4 Section 1.
May 27, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits aoxing.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2015 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction of Incorpora
May 27, 2015	EX-99.1	EX-99.1 aoxingexh991.htm Exhibit 99.1
May 15, 2015	10-Q	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, INC.
May 4, 2015	DEFA14A	Aoxing Pharmaceutical AOXING PHARMACEUTICAL COMPANY, INC.DEFA 14A 2015-05-01 aoxing.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy St
May 4, 2015	DEF 14A	Aoxing Pharmaceutical AOXING PHARMACEUTICAL COMPANY, INC. DEF 14A 2015-05-01 aoxing.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy St
April 3, 2015	8-K	Financial Statements and Exhibits, Other Events aoxing.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2015 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission
April 3, 2015	EX-99.1	NYSE MKT NOTIFIES AOXING PHARMACEUTICAL COMPANY, INC. THAT IT HAS REGAINED COMPLIANCE WITH A FINANCIAL CONDITION REQUIREMENT aoxingexh991.htm Exhibit 99.1 NYSE MKT NOTIFIES AOXING PHARMACEUTICAL COMPANY, INC. THAT IT HAS REGAINED COMPLIANCE WITH A FINANCIAL CONDITION REQUIREMENT JERSEY CITY, NEW JERSEY. April 3, 2015. Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, an
February 17, 2015	10-Q	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2014 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, IN
January 30, 2015	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2015 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S.
January 16, 2015	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K 1 aoxing.htm AOXING PHARMACEUTICAL COMPANY, INC. 8K 2015-01-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2015 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida
December 29, 2014	EX-10	奥星制药公司CFO聘用合同 Aoxing Pharmaceutical Company, Inc. CFO employment contract EX-10 2 aoxingexh10.htm AOXING PHARMACEUTICAL COMPANY CFO EMPLOYMENT AGREEMENT DATED DECEMBER 20, 2014. Exhibit 10 奥星制药公司CFO聘用合同 Aoxing Pharmaceutical Company, Inc. CFO employment contract 甲方：奥星制药公司 Party A: Aoxing Pharmaceutical Company, Inc. 乙方：周炳泉 Party B: Wilfred Chow 经甲乙双方友好协商一致同意如下条款 Party A and Party B agreed to reach the following terms and conditions after friendly negotiation. 一. 聘用 Arti
December 29, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2014 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction of Incorporation)
December 19, 2014	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2014 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S
November 14, 2014	10-Q	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, I
November 6, 2014	8-K	Unregistered Sales of Equity Securities 8-K 1 aoxing8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2014 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Juri
October 24, 2014	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2014 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S.
October 7, 2014	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 aoxing8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2014 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Juris
October 7, 2014	EX-10.A	Agreement to Purchase AXN Shares Exhibit 10-a Agreement to Purchase AXN Shares Party A: Aoxing Pharmaceutical Company, Inc.
September 29, 2014	EX-21.1	List of Subsidiaries Exhibit 21.1 List of Subsidiaries The Company has the following subsidiaries: ? Ostar Pharmaceutical, Inc., a Delaware corporation ? Hebei Aoxing Pharmaceutical Co., Inc, a PRC company
September 29, 2014	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended June 30, 2014. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, INC. (Exact Name of Registrant as S
September 2, 2014	8-K	Unregistered Sales of Equity Securities 8-K 1 aoxing8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2014 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Juris
August 6, 2014	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2014 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S. E
August 6, 2014	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2014 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S. Em
August 6, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2014 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S. Em
June 16, 2014	8-K	Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2014 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S. Em
June 16, 2014	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2014 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S. Em
May 14, 2014	10-Q	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, INC.
April 23, 2014	DEFA14A	- AOXING PHARMACEUTICAL COMPANY, INC. SCHEDULE 14AA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ]
April 23, 2014	DEF 14A	- AOXING PHARMACEUTICAL COMPANY, INC. SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ]
March 4, 2014	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K 1 aoxing8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2014 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jur
February 19, 2014	10-Q	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2013 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, IN
February 14, 2014	NT 10-Q	- UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Expires: May 31, 2012 Washington, D.
January 15, 2014	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2014 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S.
December 4, 2013	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2013 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S.
November 14, 2013	10-Q	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, I
October 30, 2013	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2013 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S.
October 15, 2013	EX-21.1	List of Subsidiaries Exhibit 21.1 List of Subsidiaries The Company has the following subsidiaries: ? Ostar Pharmaceutical, Inc., a Delaware corporation ? Hebei Aoxing Pharmaceutical Co., Inc, a PRC company
October 15, 2013	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K 1 aoxing.htm AOXING PHARMACEUTICAL COMPANY, INC. 10K 2013-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended June 30, 2013. OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 1-326
September 30, 2013	NT 10-K	- FORM 12B-25 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Expires: May 31, 2012 Washington, D.
June 13, 2013	8-K	Submission of Matters to a Vote of Security Holders - AOXING PHARMACEUTICAL COMPANY, INC. FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2013 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S. Em
May 15, 2013	10-Q	U. S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q U. S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, INC. (Name of
May 2, 2013	EX-16	May 2, 2013 EXHIBIT 16 May 2, 2013 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 In re: Aoxing Pharmaceutical Company, Inc. File#: 0-24185 FEI#: 65-0636168 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on April 29, 2013, to be filed by our former client, Aoxing Pharmaceutical Company, Inc. We agree with the statements made
May 2, 2013	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - AOXING PHARMACEUTICAL COMPANY, INC. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2013 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S. E
May 2, 2013	DEF 14A	- AOXING PHARMACEUTICAL COMPANY, INC. SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ]
May 2, 2013	DEFA14A	- AOXING PHARMACEUTICAL COMPANY, INC. SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ]
February 14, 2013	10-Q	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2012 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, IN
February 8, 2013	10-Q/A	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q/A (Amendment No. 1) United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q/A (Amendment No. 1) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARM
February 8, 2013	10-Q/A	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q/A (Amendment No. 1) United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q/A (Amendment No. 1) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARM
November 30, 2012	10-Q/A	United States Securities and Exchange Commission United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, I
November 14, 2012	10-Q	United States Securities and Exchange Commission United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, I
October 15, 2012	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended June 30, 2012. OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, INC. (Exact Name of Registrant as S
October 15, 2012	EX-21.1	List of Subsidiaries EX-21.1 2 aoxing10kexh211.htm LIST OF SUBSIDIARIES Exhibit 21.1 List of Subsidiaries The Company has the following subsidiaries · Hebei Aoxing Pharmaceutical Co., Inc, a PRC company
October 10, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - AOXING PHARMACEUTICAL COMPANY, INC. FORM 8-K OCTOBER 8, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2012 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S.
October 1, 2012	10-Q/A	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q/A (Amendment No. 1) United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q/A (Amendment No. 1) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEU
September 28, 2012	10-Q/A	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q/A (Amendment No. 1) United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q/A (Amendment No. 1) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARM
September 28, 2012	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended June 30, 2011. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, INC. (Exact Nam
September 28, 2012	NT 10-K	- AOXING PHARMACEUTICAL COMPANY, INC FORM 12B-25 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Expires: May 31, 2012 Washington, D.
September 28, 2012	10-Q/A	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q/A (Amendment No. 1) United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q/A (Amendment No. 1) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2011 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMA
August 16, 2012	8-K	Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2012 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S.
July 5, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - AOXING PHARMACEUTICAL COMPANY, INC. FORM 8-K JUNE 30, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2012 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S. Emp
June 29, 2012	8-K	Submission of Matters to a Vote of Security Holders - AOXING PHARMACEUTICAL COMPANY, INC. FORM 8-K JUNE 29, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2012 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S. Em
May 24, 2012	DEF 14A	- AOXING PHARMACEUTICAL COMPANY, INC. DEF 14A 2012-05-22 DEF 14A 1 aoxingpharmadef14a.htm AOXING PHARMACEUTICAL COMPANY, INC. DEF 14A 2012-05-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party othe
May 21, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - AOXING PHARMACEUTICAL COMPANY 8K 2012-05-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2012 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S. Emp
May 15, 2012	10-Q	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, INC.
March 22, 2012	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - AOXING PHARMACEUTICAL COMPANY, INC. FORM 8-K MARCH 19, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2012 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S. E
March 22, 2012	EX-16	March 21, 2012 EX-16 2 ex16.htm LETTER FROM PARITZ & COMPANY, P.A. DATED MARCH 21, 2012 Exhibit 16 March 21, 2012 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Dear Sirs/Madams: We have read Item 4.01 of Form 8-K for the event that occurred on March 19, 2012, to be filed by Aoxing Pharmaceutical Company, Inc. We agree with the statements made concerning our firm. Sincerely, /s/ Par
March 22, 2012	EX-99	Aoxing Pharmaceutical Company Appoints BDO China Dahua As Its Independent Auditor Exhibit 99 Aoxing Pharmaceutical Company Appoints BDO China Dahua As Its Independent Auditor Jersey City, NJ – 3/22/2012 - Aoxing Pharmaceutical Company, Inc.
February 14, 2012	10-Q	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2011 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, IN
February 14, 2012	SC 13G/A	AOXG / AOXING PHARMACEUTICAL CO INC / Wellspring Management, LLC - FINAL AMENDMENT TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Final Amendment) Aoxing Pharmaceutical Company, Inc. (Name of Issuer) Common Stock, $0.001 per share (Title of Class of Securities) 03740A106 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
December 8, 2011	EX-99.1	Aoxing Pharmaceutical Company Announces $3.2 Million Financing Exhibit 99.1 Aoxing Pharmaceutical Company Announces $3.2 Million Financing Jersey City, NJ – 12/7/2011 - Aoxing Pharmaceutical (NYSE Amex: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced that its operating subsidiary in China, Hebei Ao
December 8, 2011	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of Earliest Event Reported: December 5, 2011 AOXING PHARMACEUTICAL COMPANY, INC. (Exact Name of Company as Specified in its Charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction of Incorporation or Org
November 14, 2011	10-Q	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, I
November 4, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of Earliest Event Reported): November 3, 2011 AOXING PHARMACEUTICAL COMPANY, INC. (Exact Name of Company as Specified in its Charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction of Incorporation or Or
November 4, 2011	EX-99.1	Aoxing Pharmaceutical Company Announces Special Funding From Hebei Province in China Aoxing Pharmaceutical Company Announces Special Funding From Hebei Province in China Jersey City, NJ – 11/3/2011 - Aoxing Pharmaceutical (NYSE Amex: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced that its operating subsidiary in China, Hebei Aoxing Pharmaceutical Group Company, has received a special funding of 2 million RMB (approximately $315,000) from the Industry and Information Technology Department and the Finance Department of Hebei Province in China.
November 1, 2011	S-8	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its As filed with the Securities and Exchange Commission on November 1, 2011 Registration No.
November 1, 2011	EX-10.1	CHINA AOXING PHARM ACEUTICAL COM PANY, INC. 2006 Stock and Stock Option Plan Exhibit 10.1 CHINA AOXING PHARM ACEUTICAL COM PANY, INC. 2006 Stock and Stock Option Plan Article 1. Establishment and Purpose 1.1 Establishment of the Plan. China Aoxing Pharmaceutical Company, Inc., a Delaware corporation (the ?Company? or ?China Aoxing?), hereby establishes an incentive compensation plan (the ?Plan?), as set forth in this document. 1.2 Purpose of the Plan. The purpose of the Pl
September 28, 2011	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended June 30, 2011. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, INC. (Exact Name of Registrant as S
September 28, 2011	EX-21.1	List of Subsidiaries Exhibit 21.1 List of Subsidiaries The Company has the following subsidiaries: ? Hebei Aoxing Pharmaceutical Co., Inc, a PRC company
July 5, 2011	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 30, 2011 Date of Report (date of Earliest Event Reported) AOXING PHARMACEUTICAL COMPANY, INC. (Exact Name of Company as Specified in its Charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction of Incorporation or Organi
June 28, 2011	EX-99.1	Aoxing Pharmaceutical Company Announces Agreement on Note Conversion Note holders to Convert Approximately $6.6 million of the Company’s debt into common equity at $2.70 per share Aoxing Pharmaceutical Company Announces Agreement on Note Conversion Note holders to Convert Approximately $6.
June 28, 2011	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 26, 2011 Date of Report (date of Earliest Event Reported) AOXING PHARMACEUTICAL COMPANY, INC. (Exact Name of Company as Specified in its Charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction of Incorporation or Organi
June 28, 2011	EX-10.1	Debt Conversion Agreement Debt Conversion Agreement This Debt Conversion Agreement (this ?Agreement?), dated as of June 26, 2011, is being entered into by and between Aoxing Pharmaceuticals, Inc.
May 26, 2011	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
May 16, 2011	10-Q	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, INC.
March 7, 2011	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2011 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 0-24185 65-0636168 (State or Other Jurisdiction (Commission (I.R.S. Em
March 7, 2011	EX-99.1	EX-99.1
February 14, 2011	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aoxing Pharmaceutical Company, Inc. (Name of Issuer) Common Stock, $0.001 per share (Title of Class of S sc13gza UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aoxing Pharmaceutical Company, Inc. (Name of Issuer) Common Stock, $0.001 per share (Title of Class of Securities) 03740A106 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des
February 14, 2011	10-Q	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2010 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, IN
February 7, 2011	EX-10.A	EMPLOYMENT AGREEMENT (English version for reference only) February 1, 2011 EX-10.A 2 axn8k20110201ex10-a.htm EMPLOYMENT AGREEMENT DATED FEBRUARY 1, 2011 BETWEEN AOXING PHARMACEUTICAL COMPANY, INC. AND BOB YUNJUN AI EMPLOYMENT AGREEMENT (English version for reference only) February 1, 2011 This Agreement is made as of the 1st day of February, 2011 between Aoxing Pharmaceutical Company, Inc., with offices at 15 Exchange Place, Suite 500, Jersey City, NJ 07302 (the "Company
February 7, 2011	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: February 1, 2011 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of other jurisdiction of (IRS Employer incorporation o
December 15, 2010	RW	AOXING PHARMACEUTICAL COMPANY, INC. 15 Exchange Place, Suite 500 Jersey City, NJ 07302 AOXING PHARMACEUTICAL COMPANY, INC. 15 Exchange Place, Suite 500 Jersey City, NJ 07302 December 14, 2010 Division of Corporation Finance Securities and Exchange Commission 100 F Street Washington, DC 20549 Re: Aoxing Pharmaceutical Company, Inc. Registration Statement on Form S-3 Filed July 26, 2010 File No. 333-168305 Ladies and Gentlemen: Aoxing Pharmaceutical Company, Inc., pursuant to Rule 477
December 14, 2010	RW	AOXING PHARMACEUTICAL COMPANY, INC. 15 Exchange Place, Suite 500 Jersey City, NJ 07302 AOXING PHARMACEUTICAL COMPANY, INC. 15 Exchange Place, Suite 500 Jersey City, NJ 07302 December 14, 2010 Division of Corporation Finance Securities and Exchange Commission 100 F Street Washington, DC 20549 Re: Aoxing Pharmaceutical Company, Inc. Registration Statement on Form S-3 Filed July 26, 2010 File No. 333-168305 Ladies and Gentlemen: Aoxing Pharmaceutical Company, Inc., pursuant to Rule 477
November 15, 2010	10-Q	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, I
November 8, 2010	EX-10.A	Labor Contract 30th, December, 2009 Labor Contract Date: 30th, December, 2009 Party A?Employer?: Name: Hebei Aoxing Group Pharmaceutical Co.
November 8, 2010	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: November 1, 2010 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of other jurisdiction of (IRS Empl
November 5, 2010	EX-99	AOXING PHARMACEUTICAL ANNOUNCES MANAGEMENT CHANGES CONTACT: Investor Relations: The Trout Group Brian Korb 646-378-2923 NOT FOR IMMEDIATE RELEASE AOXING PHARMACEUTICAL ANNOUNCES MANAGEMENT CHANGES New York, NY, November 2, 2010 - Aoxing Pharmaceutical Co.
November 5, 2010	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: November 1, 2010 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of other jurisdiction of (IRS Employer incorporation o
October 4, 2010	EX-3.A	Articles of Incorporation Central American Equities Corp. Article I. Name Articles of Incorporation of Central American Equities Corp. Article I. Name The name of this Florida Corporation is: Central American Equities Corp. Article II. Address The mailing address of the Corporation is: Central American Equities Corp. P.O. Box 669 Palm Beach FL 33480 Article III. Capital Stock The Corporation shall have the authority to issue 20,000,000 shares of common stock, par value
October 4, 2010	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended June 30, 2010. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 1-32674 AOXING PHARMACEUTICAL COMPANY, INC. (Exact Name of Registrant as S
September 28, 2010	NT 10-K	UNITED STATES UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Expires: May 31, 2012 Washington, D.
July 26, 2010	EX-23.A	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 of Aoxing Pharmaceutical Company, Inc. of our report dated September 28, 2009 relating to the financial statements, which appears in Form 10-K for the year ending June 30, 2009. /s/ Paritz and Company PA Hackensack, New Jersey July 23, 2010
July 26, 2010	S-3	As filed with the Securities and Exchange Commission on July 26, 2010 As filed with the Securities and Exchange Commission on July 26, 2010 Registration Number 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AOXING PHARMACEUTICAL COMPANY, INC.
July 26, 2010	EX-4.2	FORM OF INDENTURE TO BE ENTERED INTO BETWEEN THE COMPANY AND A TRUSTEE TO BE NAMED AOXING PHARMACEUTICAL COMPANY, INC. DATED AS OF , 2010 [Name of Trustee] TABLE OF CONTENTS FORM OF INDENTURE TO BE ENTERED INTO BETWEEN THE COMPANY AND A TRUSTEE TO BE NAMED AOXING PHARMACEUTICAL COMPANY, INC.
May 17, 2010	10-Q	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-24185 AOXING PHARMACEUTICAL COMPANY, INC.
May 10, 2010	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aoxing Pharmaceutical Company, Inc. (Name of Issuer) Common Stock, $0.001 per share (Title of Class of Se UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aoxing Pharmaceutical Company, Inc. (Name of Issuer) Common Stock, $0.001 per share (Title of Class of Securities) 03740A106 (CUSIP Number) April 29, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r
April 26, 2010	EX-99.1	Aoxing Pharmaceutical Company Announces Joint Venture with Johnson Matthey PLC to Manufacture Narcotics and Neurological Pharmaceutical Products in China Joint venture to begin manufacturing in 2011; Seek SFDA approval of 8 new products Public signin April 26, 2010 Aoxing Pharmaceutical Company Announces Joint Venture with Johnson Matthey PLC to Manufacture Narcotics and Neurological Pharmaceutical Products in China Joint venture to begin manufacturing in 2011; Seek SFDA approval of 8 new products Public signing ceremony and conference call scheduled in May 2010 New York, New York, April 26, 2010 ?Aoxing Pharmaceutical Company Inc.
April 26, 2010	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: April 26, 2010 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of other jurisdiction of (IRS Employer incorporation or
April 13, 2010	8-A12B	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of other jurisdiction of incorporation or organization) (IRS Employer Identifi
March 29, 2010	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: March 19, 2010 AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of other jurisdiction of (IRS Employer incorporation or
March 29, 2010	EX-3.A	ARTICLES OF AMENDMENT ARTICLES OF INCORPORATION CHINA AOXING PHARMACEUTICAL COMPANY, INC. EX-3.A 2 caxgd8k20100319ex3-a.htm ARTICLES OF AMENDMENT TO ARTICLES OF INCORPORATION FILED ON MARCH 16, 2010, EFFECTIVE ON MARCH 19, 2010 AT 6:00 P.M. EASTERN STANDARD TIME Exhibit 3-a ARTICLES OF AMENDMENT TO ARTICLES OF INCORPORATION OF CHINA AOXING PHARMACEUTICAL COMPANY, INC. Pursuant to the provisions of section 607.1006, Florida Statues, this Florida Profit Corporation adopts the following a
March 17, 2010	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K /A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K /A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended June 30, 2009. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 0-24185 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Ex
March 4, 2010	CORRESP	CHINA AOXING PHARMACEUTICAL COMPANY, INC. 15 Exchange Place, Suite 500 Jersey City NJ 07302 CHINA AOXING PHARMACEUTICAL COMPANY, INC. 15 Exchange Place, Suite 500 Jersey City NJ 07302 646-367-1747 March 3, 2010 VIA EDGAR Jim B. Rosenberg Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: China Aoxing Pharmaceutical Company, Inc. Form 10-K for the Year Ended June 30, 2009 Form 8-K filed on August 12, 2009 File Number: 001-32674 D
February 16, 2010	10-Q	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q
January 20, 2010	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: January 18, 2010 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of other jurisdiction of (IRS Employer incorpora
January 20, 2010	EX-10.B	EXECUTIVE EMPLOYMENT AGREEMENT EX-10.B 3 caxg8k20100118ex10b.htm EXECUTIVE EMPLOYMENT AGREEMENT DATED AS OF JANUARY 13, 2010 BETWEEN CHINA AOXING PHARMACEUTICAL COMPANY, INC. AND HUI SHAO Exhibit 10-b EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of January 13, 2010 by and between China Aoxing Pharmaceutical Company, Inc, a company incorporated under the laws of the Flor
January 20, 2010	EX-10.A	EXECUTIVE EMPLOYMENT AGREEMENT EX-10.A 2 caxg8k20100118ex10a.htm EXECUTIVE EMPLOYMENT AGREEMENT DATED AS OF JANUARY 13, 2010 BETWEEN CHINA AOXING PHARMACEUTICAL COMPANY, INC. AND ZHENJIANG YUE Exhibit 10-a EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of January 13, 2010 by and between China Aoxing Pharmaceutical Company, Inc, a company incorporated under the laws of the
January 7, 2010	EX-3	ARTICLES OF AMENDMENT ARTICLES OF INCORPORATION OF CHINA AOXING PHARMACEUTICAL COMPANY, INC. Exhibit 3-a ARTICLES OF AMENDMENT TO ARTICLES OF INCORPORATION OF CHINA AOXING PHARMACEUTICAL COMPANY, INC.
January 7, 2010	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: January 6, 2010 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of other jurisdiction of incorporation or organiz
December 15, 2009	DEF 14C	SCHEDULE 14C (Rule 14c-101) INFORMATION REQUIRED IN INFORMATION STATEMENT Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 SCHEDULE 14C (Rule 14c-101) INFORMATION REQUIRED IN INFORMATION STATEMENT Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for use of the Commission only [x ] Definitive Information Statement China Aoxing Pharmaceutical Company, Inc.
December 2, 2009	CORRESP	CHINA AOXING PHARMACEUTICAL COMPANY, INC. 15 Exchange Place, Suite 500 Jersey City, NY 07302 CHINA AOXING PHARMACEUTICAL COMPANY, INC. 15 Exchange Place, Suite 500 Jersey City, NY 07302 646-367-1747 December 2, 2009 VIA EDGAR Jeffrey Riedler Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: China Aoxing Pharmaceutical Company, Inc. Preliminary Information Statement on Schedule 14C Filed November 23, 2009 File No. 001-32674 Dear
November 30, 2009	EX-14	Code of Ethics of China Aoxing Pharmaceutical Company, Inc. CODE OF ETHICS OF CHINA AOXING PHARMACEUTICAL COMPANY, INC. APPLICABLE TO DIRECTORS, OFFICERS AND EMPLOYEES Adopted as of October 28, 2008 The Ethics Committee (the ?Committee?) of the Board of Directors of CHINA AOXING PHARMACEUTICAL COMPANY, INC. shall consist of a minimum of three directors. The Charter of the Committee and its structure shall refer to that of the Audit Committee, which the Com
November 30, 2009	8-K	Amendment to Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: October 28, 2008 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of other jurisdiction of (IRS Employer incorpora
November 23, 2009	PRE 14C	SCHEDULE 14C (Rule 14c-101) INFORMATION REQUIRED IN INFORMATION STATEMENT Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 SCHEDULE 14C (Rule 14c-101) INFORMATION REQUIRED IN INFORMATION STATEMENT Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [x ] Preliminary Information Statement [ ] Confidential, for use of the Commission only [ ] Definitive Information Statement China Aoxing Pharmaceutical Company, Inc.
November 23, 2009	10-Q	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2009 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-24185 CHINA AOXING PHARMACEUTICAL COMP
November 16, 2009	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits 8-K 1 chaox8kbylaws2009.htm CHINA AOXING 8-K - AMENDED BY LAWS OCT 2009 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: October 18, 2009 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Fl
November 16, 2009	NT 10-Q	UNITED STATES UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Expires: August 31, 2009 Washington, D.
November 16, 2009	EX-3	AMENDED AND RESTATED BYLAWS CHINA AOXING PHARMACEUTICAL COMPANY, INC. ARTICLE I. DIRECTORS AMENDED AND RESTATED BYLAWS OF CHINA AOXING PHARMACEUTICAL COMPANY, INC. ARTICLE I. DIRECTORS Section 1. Function. All corporate powers shall be exercised by or under the authority of the Board of Directors. The business and affairs of the Corporation shall be managed under the direction of the Board of Directors. Directors must be natural persons who are at least 18 years of age but need not be s
October 14, 2009	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended June 30, 2009. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 0-24185 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exact Name of Registran
September 28, 2009	NT 10-K	UNITED STATES UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Expires: August 31, 2009 Washington, D.
September 24, 2009	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended June 30, 2007. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 0-24185 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exa
September 24, 2009	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended June 30, 2006. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 0-24185 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exa
August 12, 2009	EX-10.A	SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July 31, 2009, between China Aoxing Pharmaceutical Company, Inc.
August 12, 2009	8-K	Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: August 6, 2009 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of other jurisdiction of (IRS Employer incorporati
August 3, 2009	EX-99	China Aoxing Pharmaceutical Company Announces Private Placement of Common Stock EX-99 2 chaox8krule135cnoticeexh99.htm CHINA AOXING 8K- RULE 135C NOTICE - EXH 99 China Aoxing Pharmaceutical Company Announces Private Placement of Common Stock New York, August 3, 2009 – China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) (“China Aoxing”), today announced that it is making a private offering of the Company’s common stock at a purchase price of $0.95 per share, for gross proc
August 3, 2009	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: August 3, 2009 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of Other Jurisdiction of incorporation or organiza
May 15, 2009	10-Q	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2009 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-24185 CHINA AOXING PHARMACEUTICAL COMPANY,
April 10, 2009	CORRESP	CHINA AOXING PHARMACEUTICAL COMPANY, INC. 40 Wall Street, Floor 28 New York, NY 10005 (Tel) 646 - 512- 5662 (Fax) 646 - 512- 5663 CHINA AOXING PHARMACEUTICAL COMPANY, INC. 40 Wall Street, Floor 28 New York, NY 10005 (Tel) 646 - 512- 5662 (Fax) 646 - 512- 5663 April 9, 2009 VIA EDGAR Jim B. Rosenberg Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: China Aoxing Pharmaceutical Company, Inc. Form 10-KSB for the fiscal year ended June 30, 2008 Form 10-KSB for the fisc
February 17, 2009	10-Q	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2008 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-24185 CHINA AOXING PHARMACEUTICAL COMPA
January 26, 2009	CORRESP	CHINA AOXING PHARMACEUTICAL COMPANY, INC. 40 Wall Street, Floor 28 New York, NY 10005 (Tel) 646 - 512- 5662 (Fax) 646 - 512- 5663 CHINA AOXING PHARMACEUTICAL COMPANY, INC CHINA AOXING PHARMACEUTICAL COMPANY, INC.
November 18, 2008	10-Q	United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2008 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-24185 CHINA AOXING PHARMACEUTICAL COMP
November 17, 2008	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: November 10, 2008 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of Other Jurisdiction of incorporation or organ
November 14, 2008	NT 10-Q	SECURITIES & EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Notification of Late Filing CHINA AOXING PHARMACEUTICAL COMPANY, INC. Commission File Number 0-24185 SECURITIES & EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Notification of Late Filing CHINA AOXING PHARMACEUTICAL COMPANY, INC. Commission File Number 0-24185 (Check one) [ ] Form 10-K and Form 10-KSB [ ] Form 11-K [ ] Form 20-F [X] Form 10-Q and Form 10-QSB [ ] Form N-SAR [ ] Form N-CSR For the period ended: September 30, 2008 [ ] Transition Report on Form 10-K and Form 10-KSB [ ] Trans
November 10, 2008	CORRESP	CHINA AOXING PHARMACEUTICAL COMPANY, INC. 40 Wall Street, Floor 28 New York, NY 10005 (Tel) 646 - 512- 5662 (Fax) 646 - 512- 5663 CHINA AOXING PHARMACEUTICAL COMPANY, INC. 40 Wall Street, Floor 28 New York, NY 10005 (Tel) 646 - 512- 5662 (Fax) 646 - 512- 5663 November 05, 2008 VIA EDGAR Jim B. Rosenberg Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: China Aoxing Pharmaceutical Company, Inc. Form 10-KSB for the fiscal year ended June 30, 2007 File No. 001-32674 D
October 14, 2008	10KSB	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended June 30, 2008. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 0-24185 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Name of Small Busines
September 29, 2008	NT 10-K	SECURITIES & EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Notification of Late Filing CHINA AOXING PHARMACEUTICAL COMPANY, INC. Commission File Number 0-24185 SECURITIES & EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Notification of Late Filing CHINA AOXING PHARMACEUTICAL COMPANY, INC. Commission File Number 0-24185 (Check one) [X] Form 10-K and Form 10-KSB [ ] Form 11-K [ ] Form 20-F [ ] Form 10-Q and Form 10-QSB [ ] Form N-SAR [ ] Form N-CSR For the period ended: June 30, 2008 [ ] Transition Report on Form 10-K and Form 10-KSB [ ] Transition
September 2, 2008	CORRESP	CHINA AOXING PHARMACEUTICAL COMPANY, INC. 40 Wall Street, 28th Floor New York, NY 10005 CHINA AOXING PHARMACEUTICAL COMPANY, INC. 40 Wall Street, 28th Floor New York, NY 10005 646-512-5662 September 2, 2008 VIA EDGAR Jim B. Rosenberg Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: China Aoxing Pharmaceutical Company, Inc. Form 10-KSB for the fiscal year ended June 30, 2007 File No. 001-32674 Dear Mr. Rosenberg: I am writi
August 20, 2008	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: August 12, 2008 CHINA AOXING PHARMACEU UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: August 12, 2008 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of Other Jurisdiction of incorporat
August 20, 2008	EX-10	AMENDED JUNIOR SUBORDINATED PROMISSORY NOTE AMENDED JUNIOR SUBORDINATED PROMISSORY NOTE Date of Issue: May 1, 2008 Date of Amendment: August 12, 2008 Principal Amount: RMB 24,000,000.
August 20, 2008	EX-10	CONVERTIBLE TERM NOTE THIS NOTE AND THE COMMON SHARES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS.
August 20, 2008	8-K	Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: August 15, 2008 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of Other Jurisdiction of incorporation or organiz
August 6, 2008	CORRESP	CHINA AOXING PHARMACEUTICAL COMPANY, INC. 40 Wall Street, 28th Fl New York, NY 10005 November 1, 2005 CHINA AOXING PHARMACEUTICAL COMPANY, INC. 40 Wall Street, 28th Fl New York, NY 10005 646-512-5662 August 6, 2008 VIA EDGAR Jim B. Rosenberg Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: China Aoxing Pharmaceutical Company, Inc. Form 10-KSB for the fiscal year ended June 30, 2007 File No. 001-32674 Dear Mr. Rosenberg:
July 2, 2008	CORRESP	CHINA AOXING PHARMACEUTICAL COMPANY, INC. 444 Washington Boulevard, Unit 2424 Jersey City, NY 07310 CHINA AOXING PHARMACEUTICAL COMPANY, INC. 444 Washington Boulevard, Unit 2424 Jersey City, NY 07310 201-420-1076 July 1, 2008 VIA EDGAR Jim B. Rosenberg Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: China Aoxing Pharmaceutical Company, Inc. Form 10-KSB for the fiscal year ended June 30, 2007 File No. 001-32674 Dear Mr. Rosenberg: I a
May 15, 2008	8-K/A	Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: April 16, 2008 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of other jurisdiction of (IRS
May 15, 2008	10QSB	U. S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-QSB [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2008 [ ] TRANSITION REPORT UNDER SECTION 13 OR U. S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-QSB [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2008 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-24185 CHINA AOXING PHARMACEUTICAL COMPANY, INC.
May 5, 2008	8-K	Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: May 1, 2008 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of Other Jurisdiction of incorporation or organizatio
May 5, 2008	EX-10	JUNIOR SUBORDINATED PROMISSORY NOTE JUNIOR SUBORDINATED PROMISSORY NOTE JUNIOR SUBORDINATED PROMISSORY NOTE Date of Issue: May 1, 2008 Principal Amount: USD $3,420,000.
April 25, 2008	SC 13D	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2(a) (Amendment No. ) China UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ?240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ?240.13d-2(a) (Amendment No. ) China Aoxing Pharmaceutical Company, Inc. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 16937H106 (CUSIP Number)
April 25, 2008	EX-10.1	JOINT STRATEGIC ALLIANCE AND SECURITIES PURCHASE AGREEMENT Exhibit 10.1 JOINT STRATEGIC ALLIANCE AND SECURITIES PURCHASE AGREEMENT THIS JOINT STRATEGIC ALLIANCE AND SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of April 15, 2008, is made and entered into by and between American Oriental Bioengineering Inc., a corporation organized under the laws of the State of Nevada (?AOBO? or the ?Investor?), and China Aoxing Pharmaceutical Company, Inc.,
April 21, 2008	8-K	Changes in Control of Registrant, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: April 15, 2008 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of Other Jurisdiction of incorporation or organiza
April 21, 2008	EX-10	JOINT STRATEGIC ALLIANCE AND SECURITIES PURCHASE AGREEMENT JOINT STRATEGIC ALLIANCE AND SECURITIES PURCHASE AGREEMENT THIS JOINT STRATEGIC ALLIANCE AND SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of April 15, 2008, is made and entered into by and between American Oriental Bioengineering Inc.
April 21, 2008	8-K	Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: April 16, 2008 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of Other Jurisdiction of incorporation or organiza
April 14, 2008	CORRESP	CHINA AOXING PHARMACEUTICAL COMPANY, INC. 444 Washington Boulevard, Unit 2424 Jersey City, NY 07310 CHINA AOXING PHARMACEUTICAL COMPANY, INC. 444 Washington Boulevard, Unit 2424 Jersey City, NY 07310 201-420-1075 April 14, 2008 VIA EDGAR Jim B. Rosenberg Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: China Aoxing Pharmaceutical Company, Inc. Form 10-KSB for the fiscal year ended June 30, 2007 File No. 001-32674 Dear Mr. Rosenberg: I
March 31, 2008	CORRESP	CHINA AOXING PHARMACEUTICAL COMPANY, INC. 444 Washington Boulevard, Unit 2424 Jersey City, NY 07310 November 1, 2005 CHINA AOXING PHARMACEUTICAL COMPANY, INC. 444 Washington Boulevard, Unit 2424 Jersey City, NY 07310 201-420-1076 March 31, 2008 VIA EDGAR Jim B. Rosenberg Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: China Aoxing Pharmaceutical Company, Inc. Form 10-KSB for the fiscal year ended June 30, 2007 File No. 001-32674 Dear
March 13, 2008	CORRESP	CHINA AOXING PHARMACEUTICAL COMPANY, INC. 444 Washington Boulevard, Unit 2424 Jersey City, NY 07310 CHINA AOXING PHARMACEUTICAL COMPANY, INC. 444 Washington Boulevard, Unit 2424 Jersey City, NY 07310 201-420-1076 March 13, 2008 VIA EDGAR Jim B. Rosenberg Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: China Aoxing Pharmaceutical Company, Inc. Form 10-KSB for the fiscal year ended June 30, 2007 File No. 001-32674 Dear Mr. Rosenberg: I
March 13, 2008	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: March 11, 2008 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of Other Jurisdiction of incorporation or organiza
March 13, 2008	EX-99	China Aoxing Pharmaceutical Company Signed Definitive Acquisition Agreement to Acquire Shijiazhuang Lerentang Pharmaceutical Company, Ltd. - Acquisition to Expand Company’s Market Position and Portfolio in Pain Management - China Aoxing Pharmaceutical Company Signed Definitive Acquisition Agreement to Acquire Shijiazhuang Lerentang Pharmaceutical Company, Ltd.
March 13, 2008	EX-10	ACQUISITION AGREEMENT ACQUISITION AGREEMENT THIS ACQUISITION AGREEMENT (this "Agreement") is dated as of March 11, 2008, by and among China Aoxing Pharmaceutical Company Inc, a Florida Corporation (the "Purchasers", "CAXG" or the "Company"), Shijiazhuang Lerentang Pharmaceutical Company Limited, a Chinese corporation ("LRT" or the "Acquiree").
March 5, 2008	EX-7	Securities and Exchange Commission Securities and Exchange Commission Washington, D.C. 20549 Gentlemen: We have read Item 4.02 of the Current Report on Form 8-K of China Aoxing Pharmaceutical Company, Inc. for February 28, 2008, and we agree with the statements contained therein insofar as they relate to our Firm. Very truly yours, /s/ Paritz & Company Paritz and Company PA
March 5, 2008	8-K	Financial Statements and Exhibits, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: February 28, 2008 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of Other Jurisdiction of incorporation or organ
February 19, 2008	10QSB	U. S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-QSB U. S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-QSB [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2007 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-24185 CHINA AOXING PHARMACEUTICAL COMPANY, IN
February 14, 2008	NT 10-Q	SECURITIES & EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Notification of Late Filing CHINA AOXING PHARMACEUTICAL COMPANY, INC. Commission File Number 0-24185 SECURITIES & EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Notification of Late Filing CHINA AOXING PHARMACEUTICAL COMPANY, INC. Commission File Number 0-24185 (Check one) [ ] Form 10-K and Form 10-KSB [ ] Form 11-K [ ] Form 20-F [X] Form 10-Q and Form 10-QSB [ ] Form N-SAR [ ] Form N-CSR For the period ended: December 31, 2007 [ ] Transition Report on Form 10-K and Form 10-KSB [ ] Transi
November 14, 2007	10QSB	U. S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-QSB U. S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-QSB [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2007 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-24185 CHINA AOXING PHARMACEUTICAL COMPANY, I
November 7, 2007	EX-99.2	China Aoxing Pharmaceutical Will Present at the Third Annual Adam Friedman China Growth Conference on November 7 and Will File Its Presentation with the SEC as a Form 8K China Aoxing Pharmaceutical Will Present at the Third Annual Adam Friedman China Growth Conference on November 7 and Will File Its Presentation with the SEC as a Form 8K New York, November 06, 2007 (PR Newswire) ? China Aoxing Pharmaceutical Company, Inc.
November 7, 2007	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: November 7, 2007 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida (State of other jurisdiction of incorporation or organization) 65-
November 7, 2007	EX-99.1	EX-99.1
September 28, 2007	10KSB	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB (Mark one) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: June 30, 2007 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-24185 CHINA AOXING PHAR
September 6, 2007	EX-99	China Aoxing Pharmaceutical Company Receives Government Approval for Increased Ownership of its Main Operating Subsidiary, Hebei Aoxing; Amends Terms of the Acquisition Agreement EX-99 3 chaox8kyueexh99.htm CHINA AOXING 8-K YUE CONTRACT EXH 99 China Aoxing Pharmaceutical Company Receives Government Approval for Increased Ownership of its Main Operating Subsidiary, Hebei Aoxing; Amends Terms of the Acquisition Agreement NEW YORK, September 6, 2007 - China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG), a China-based pharmaceutical company specializing in analgesics and p
September 6, 2007	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: September 4, 2007 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of Other Jurisdiction of incorporation or organ
September 6, 2007	EX-10	Agreement Between China Aoxing Pharmaceutical Company and Mr Zhenjiang Yue Agreement Between China Aoxing Pharmaceutical Company and Mr Zhenjiang Yue On September 4, 2007, China Aoxing Pharmaceutical Company (?China Aoxing?) and Mr.
July 2, 2007	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: June 27, 2007 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of Other Jurisdiction of incorporation or organizat
May 15, 2007	10QSB	U. S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-QSB U. S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-QSB [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2007 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-24185 CHINA AOXING PHARMACEUTICAL COMPANY, INC.
March 26, 2007	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: January 22, 2007 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida (State of other jurisdiction of incorporation or organization) 65-
February 21, 2007	10QSB	U. S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-QSB U. S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-QSB [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2006 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-24185 CHINA AOXING PHARMACEUTICAL COMPANY, IN
February 14, 2007	NT 10-Q	SECURITIES & EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Notification of Late Filing CHINA AOXING PHARMACEUTICAL COMPANY, INC. Commission File Number 0-24185 SECURITIES & EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Notification of Late Filing CHINA AOXING PHARMACEUTICAL COMPANY, INC. Commission File Number 0-24185 (Check one) [ ] Form 10-K and Form 10-KSB [ ] Form 11-K [ ] Form 20-F [X] Form 10-Q and Form 10-QSB [ ] Form N-SAR [ ] Form N-CSR For the period ended: December 31, 2006 [ ] Transition Report on Form 10-K and Form 10-KSB [ ] Transi
February 7, 2007	SB-2/A	As filed with the Securities and Exchange Commission on February 7, 2007 Registration Number 333-138643 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SB-2/A (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CHIN As filed with the Securities and Exchange Commission on February 7, 2007 Registration Number 333-138643 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SB-2/A (Amendment No.
January 26, 2007	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO.: 0-24185 Date of Report: January 22, 2007 CHINA AOXING PHARMACEUTICAL COMPANY, INC. (Exact name of registrant as specified in its charter) Florida 65-0636168 (State of Other Jurisdiction of incorporation or organi
November 14, 2006	10QSB	U. S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-QSB U. S. Securities and Exchange Commission Washington, D. C. 20549 FORM 10-QSB [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2006 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-24185 CHINA AOXING PHARMACEUTICAL COMPANY, I
December 17, 2002	4	/s/ Michael Nicholas Caggiano 12/10/02 Signature of Reporting Person Date FORM 4 o Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). (Print or Type Responses) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1

AOXG / Aoxing Pharmaceutical Company, Inc. - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Grundläggande statistik

SEC Filings

SEC Filings (Chronological Order)